

Clinical value of contrast-enhanced computed tomography (CECT) combined with contrast-enhanced ultrasound (CEUS) for characterization and diagnosis of small nodular lesions in liver

Jia-lian Liu¹, Dong Bao², Zong-li Xu³, Xiang-ju Zhuge⁴

ABSTRACT

Objectives: To explore the clinical value of contrast-enhanced computed tomography (CECT) combined with contrast-enhanced ultrasound (CEUS) for characterization and diagnosis of small nodular lesions in the liver and investigate the association between such small nodular lesions and the degree of tumor differentiation.

Methods: Combined imaging modalities were performed on 120 patients who were admitted by Linyi Maternal and Child Health hospital from December 2018 to December 2020 and diagnosed with hepatic nodular lesions. The CT scans were interpreted by two senior imageologists while the ultrasound scans were analyzed by two senior sonographers. A comparative analysis was carried out on different scan modes and the postoperative or post-puncture pathological results using the t-test, the x² test, and the Pearson's correlation analysis.

Results: Compared to the pathological results, definite diagnoses of 55 malignant cases were made using CECT alone, with the coincidence rate of 78.6%; CECT combined with CEUS formed correct diagnoses in 64 cases, and the coincidence rate was up to 91.4%. The difference between the two scan modes was statistically significant ($p=0.03$). Based on pathological diagnosis, seventy out of the 120 cases of small nodular lesions were identified as malignant, while the other 50 cases were benign. The single imaging modality diagnosed 63 malignant and 57 benign nodules, whereas the combined modalities identified 68 malignancies and 52 benign conditions. Compared to CECT as a single imaging modality, the combined modalities showed a higher degree of sensitivity and accuracy, and the difference was statistically significant (sensitivity: $p=0.03$; accuracy: $p=0.02$); in the malignant cases, the magnitudes of contrast enhancement of CT and ultrasound imaging decreased with an increase in the degree of differentiation, indicating a negative correlation between these factors.

Conclusions: CECT combined with CEUS has a higher coincidence rate, greater sensitivity, and better diagnostic accuracy when being used for characterization and diagnosis of small nodular lesions in the liver. A higher degree of tumor differentiation means a decreased magnitude of contrast enhancement and a blurrier boundary, which indicates that CECT and CEUS are complementary to each other in classifying malignant liver nodules. The use of the combined imaging modalities shows clinical value for characterizing small liver nodules and predicting the degree of malignancy.

KEYWORDS: Contrast-enhanced computed tomography, Ultrasound imaging, Small liver nodules, Degree of differentiation, Characterization and diagnosis.

doi: <https://doi.org/10.12669/pjms.37.7.4306>

How to cite this:

Liu J, Bao D, Xu Z, Zhuge X. Clinical value of contrast-enhanced computed tomography (CECT) combined with contrast-enhanced ultrasound (CEUS) for characterization and diagnosis of small nodular lesions in liver. *Pak J Med Sci.* 2021;37(7):1843-1848. doi: <https://doi.org/10.12669/pjms.37.7.4306>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence:
Xiang-ju Zhuge,

- * Received for Publication: February 20, 2021
- * Revision Received: June 14, 2021
- * Revision Accepted: July 3, 2021

INTRODUCTION

Liver cancer is a commonly seen gastrointestinal malignancy. With a higher degree of malignancy

indicating an increased risk of death, the disease can be a life-threatening challenge.¹ About 80% of hepatocellular carcinoma (HCC) cases occur after chronic hepatitis and cirrhosis.² With an insidious onset and a lack of characteristic clinical signs and symptoms, it is relatively difficult to diagnose liver cancer at the very early stage.³ Early characterization and diagnosis of liver cancer have clinical significance for choosing treatment options and predicting prognosis. Generally, CT scans of the liver are blurred by the abundant blood supply, and there is noise interference. Reportedly, the sensitivity of CT in the detection of liver nodules, especially the smaller ones, is relatively low.⁴ Therefore, Other complementary methods are needed to improve the detection rate.⁵ CEUS surveillance is a safe, cost-effective, and highly accurate imaging modality widely used for the detection of malignant focal liver lesions based on exclusive ultrasonic sequences and FDA-approved microbubbles. CEUS enables real-time representation of dynamic events, making it an ideal complement to CT and MRI for the characterization of indeterminate lesions.⁶ The use of CECT combined with CEUS has clinical value in that it supports the characterization and diagnosis of small nodular lesions in the liver and improves prediction of malignant lesions. Details are reported as follows:

METHODS

Ethical approval: The study was approved by the Institutional Ethics Committee of Linyi Maternal and Child Health Hospital (No.LCH20210202058), and written informed consent was obtained from all participants.

Inclusion criteria: (1) Imageology indicated small nodular lesions (≤ 5 cm) in the liver;⁷ (2) Definitive diagnosis was given after operation or biopsy, and pathological results were available;⁸ (3) CECT and CEUS surveillance were performed within a month (30 days) before operation or biopsy; (4) No multiple but solitary lesion was detected; (5) Complete clinical materials were available; (6) The patient, with clear consciousness, had no history of mental disorder; (7) The patient and his/her family agreed to this study, and the patient was cooperative and compliant throughout the treatment course.

Exclusion criteria: (1) It was not the first time for the patient to seek medical attention because of the liver condition; (2) Tumors were detected in the liver and another part of the body; (3) The patient had severe primary comorbidities in other tissues,

accompanied by serious pleural effusion and ascites and jaundice; (4) Clinical or pathological materials were incomplete; (5) The patient was not able to participate in the study independently because of mental or cognitive disorder; (6) Multiple lesions were detected.

This study included 120 patients who were admitted by Linyi Maternal and Child Health hospital from December 2018 to December 2020 and diagnosed with hepatic nodular lesions. These patients were divided into a malignant group and a benign group by their pathological results. The malignant group was formed by 70 patients, including 43 males and 27 females aged between 54 and 71 (mean age: 62.81 ± 6.72 , max. nodule diameter: 3.31 ± 1.20 cm, course of disease: 1.31 ± 0.55 yrs). In the benign group, there were 31 males and 19 females at the age between 52 and 70 (mean age: 61.39 ± 7.35 , max. nodule diameter: 2.83 ± 1.04 cm, course of disease: 2.06 ± 0.49 yrs). There was no statistically significant difference between the two groups in sex, age, and other demographic data, indicating intergroup comparability in these aspects (Table-I). Nodular lesions in the malignant group had a diameter larger than the benign ones, and the difference was statistically significant ($p = 0.02$). Compared with the benign group, the malignant group had a shorter course of disease, and the difference had statistical significance ($p = 0.00$). In terms of pathological results, the malignant group was comprised of HCC ($n = 58$), cholangiocellular carcinoma (CCC, $n = 7$), and mixed tumors ($n = 5$); the benign group consisted of focal nodular hyperplasia (FNH, $n = 32$), hepatic adenoma (HA, $n = 9$), hepatic cystadenoma (HCA, $n = 6$), and chronic granulomatous disease (CGD, $n = 3$).

The patient who refrained from eating as required was placed in a supine position for routine plain CT scanning using a Philips 64-slice helical CT scanner, with the slice thickness of 4 mm and the slice gap of 5 mm. After the plain CT scanning, 80 mL of iohexol was injected into the ulnar vein with a high-pressure syringe at the flow rate of 3-4 ml/s. Arterial-phase CT imaging started 24-26 s after the injection, followed by portal venous- and late washout-phase imaging (45-60 s and 120-180 s delay, respectively). The degree of contrast enhancement of the lesion was observed.

Ultrasound microvascular imaging (UMI): The patient was asked to fast several hours prior to scanning, and a 3-5 MHz Philips color doppler ultrasound scanner with a convex array probe was used for UMI with the patient lying in a supine

Table-I: Malignant group vs. benign group: demographic data ($\bar{X}\pm S$).

Indicator	Malignant Group (n= 70)	Benign Group (n= 50)	t/ χ^2	p
Age*	62.81±6.72	61.39±7.35	0.20	0.27
Male (n/ %)*	43 (61%)	31 (62%)	0.00	0.95
Nodule diameter (cm) Δ	3.31±1.20	2.83±1.04	2.30	0.02
Course of disease (yrs) Δ	1.31±0.55	2.06±0.49	7.70	0.00

*p>0.05; Δ <0.05.

position. Before the procedure, the patient and his/her family were informed of possible adverse reactions to UMI. First of all, routine ultrasound imaging was performed to read the location, shape, and size of the nodular lesion. The target nodule was subject to ultrasound imaging surveillance. Bracco Sono Vuc (a contrast agent) was mixed with 5 mL normal saline to prepare microbubble suspension.⁹ The contrast agent (2 mL) was administered with ulnar vein injection, followed by washing with 5.0 mL of normal saline. The patient was asked to control his/her breath before setting the timer for 60 s, during which period, real-time scanning of perfusion occurred. This process was divided into three phases, including the arterial phase (10-30 s), the portal venous phase (30-120 s), and the late washout-phase (180-360 s). Real-time ultrasound imaging was useful to observe the features of a tumor. The degree of contrast enhancement was classified as low, medium, and high.¹⁰ All test results were assessed by two senior imageologists and two senior sonographers.

Outcome measures: (1) Calculating the coincidence rates of different imaging modalities in relation to the pathological results; (2) Comparing the sensitivity, specificity, and accuracy of the single and combined imaging modalities for the characterization of small nodular lesions in the liver, with the pathological results as the standard of diagnosis; (3) Analyzing

the correlations between liver nodules at a varying degree of malignancy and the results produced by the combined imaging modalities.

Statistical Analysis: Statistical analysis was performed using SPSS 20.0, with the measurement data being represented by ($\bar{X}\pm S$). Intergroup comparison was examined with the independent-samples t-test, and the comparison of rates was examined with the χ^2 test. Correlations were expressed by Pearson's correlation coefficients. P<0.05 was considered statistically significant.

RESULTS

Comparing the detection rates of the single and combined imaging modalities to the pathological results (Table-II), CECT alone identified 55 malignant nodules, and the coincidence rate was 78.6% (55/70); the combined imaging modalities formed definite diagnosis of 64 malignant cases, and the coincidence rate was 91.4% (64/70). There is a significant difference between these techniques (p= 0.03).

According to the pathological results, there were 70 malignant cases and 50 benign cases. When different imaging modalities were used for characterization and diagnosis, sixty-three malignancies and 57 benign nodules were detected using CECT alone, whereas 68 malignancies and 52 benign cases were identified with the combined

Table-II: Coincidence rates of different imaging modalities in relation to pathological results ($\bar{X}\pm S$), n=70.

Group	Malignant Cases	Malignant Cases Confirmed by Pathological Diagnosis	Coincidence Rate*
CECT	55	70	78.6%
CECT combined with CEUS	64	70	91.4%
χ^2			4.53
P			0.03

*p<0.05.

Table-III: Correlation analysis of malignant and benign tumors identified by the single and combined imaging modalities in relation to the pathological results.

Pathological Results	CECT			CECT combined with CEUS		
	Malignant Cases	Benign Cases	Total	Malignant Cases	Benign Cases	Total
Malignant Cases	55	15	70	64	6	70
Benign Cases	8	42	50	4	46	50
Total	63	57	120	68	52	120

Table-IV: Diagnostic sensitivity, specificity, and accuracy of the single and combined imaging modalities.

Group	Sensitivity*	Specificity	Accuracy*
CECT	(55/70)	88.33% (110/120)	69.17% (97/120)
CECT combined with CEUS	(64/70)	91.42% (46/50)	88.33% (110/120)
χ^2	4.53	0.52	5.94
p	0.03	0.21	0.02

*p<0.05.

imaging modalities. The combined imaging modalities outperformed the single imaging modality in screening sensitivity and diagnostic accuracy, and the difference was statistically significant (sensitivity: p= 0.03; accuracy: p= 0.02). Tables-III & IV.

Correlation analysis showed that the degrees of contrast enhancement of CT and UMI were reduced as the differentiation degree of a malignant liver nodule increased, indicating a negative correlation between the degree of contrast enhancement of CT and UMI and the degree of tumor differentiation (Table-V). In other words, CT and UMI are two complementary modalities for the determination of differentiation degrees of malignant liver nodules.

DISCUSSION

Cirrhotic nodules and HCC are two types of space-occupying liver lesions commonly seen in clinical practice.¹¹ HCC mostly occurs after chronic hepatitis and cirrhosis. It is difficult to make an early diagnosis of HCC because the disease has no specific clinical signs and symptoms in early stages. For space-occupying liver lesions, accurate diagnosis and timely intervention during the early onset are critical to improve the prognosis and quality of life.¹² In clinical practice, despite the detection of alpha-fetoprotein (AFP) and

other tumor markers,¹³ imageology still plays a fundamental role in deciding treatment regimens and predicting prognosis.¹⁴

CECT as an imaging technique is based on the theory of hepatic arterial blood supply to the focal liver lesion.¹⁵ With tissue or vascular specific contrast agents, CT has become a powerful tool to monitor tumor growth in animal livers.¹⁶ CECT is able to grasp the "fast-in and out" feature of HCC lesions and exhibit the blood flow in the tumor.¹⁷

A normal liver derives 80% of its blood from the portal vein and the other 20% from the hepatic artery. CECT is characterized by efficient scanning and high diagnostic accuracy as it supports total liver scanning during the arterial and portal venous phases, respectively.¹⁸ However, in clinical practice, the surrounding blood flow may interfere with the detection of smaller nodules or focal liver lesions. Besides, it is sometimes difficult to distinguish benign lesions from HCC lesions. All this has

Table-V: Correlations between different pathological patterns and UMI results.

Differentiation Degree	CECT	UMI
Low differentiation	-0.37	-0.41
Medium differentiation	-0.32	-0.36
High differentiation	-0.28	-0.22

imposed a radical challenge to the characterization and diagnosis of HCC. CT and MRI occasionally fail in characterizing indeterminate liver lesions.

As a unique imaging modality that supports purely intravascular contrast agents and enables real-time evaluation of contrast enhancement, CEUS is an ideal complement to CT or MRI for the characterization of indeterminate liver lesions.¹⁹ Ultrasound imaging has recently obtained approval of the U.S. Food and Drug Administration (FDA) for detection of liver injury. Zarzour et al.²⁰ pointed out that ultrasound imaging had clinical value in distinguishing benign liver lesions from malignant ones. Ultrasound imaging uses inert gases as contrast agents and depicts the histological features of the liver based on the blood perfusion of liver nodules and the acoustic differences between the liver nodules and the normal liver parenchyma.²¹ A clinical research discovered that most cirrhotic nodules convert to high-grade dysplastic nodules by forming low-grade dysplastic nodules (LGDNs) through nodular regeneration, and eventually develop into early HCCs; therefore, hepatocellular development is considered part of the process of angiogenesis and vascularization.²² Tumor angiogenesis is characterized by unpaired arteries and sinusoidal capillarization,²³ which provides a theoretical basis for the characterization of relevant vascular patterns on suspicious sites. As a radiation-free and cost-effective imaging modality that enables real-time monitoring, CEUS has been extensively used in the diagnosis of liver cancer.²⁴ However, unlike other types of liver cancer, cirrhosis causes substantial damage to the liver structure. Moreover, it is difficult to distinguish cirrhotic nodules from space-occupying lesions associated with early-stage liver cancer. Therefore, CEUS is viewed as a favorable complement to CT or MRI for the diagnosis of HCC in a cirrhotic liver.²⁵

This study revealed that using CECT alone could yield a coincidence rate of 78.6% whereas CECT combined with CEUS had a coincidence rate of 91.4%, and the difference was statistically significant ($p=0.03$); According to the pathological results, 70 out of the 120 patients had malignant focal liver lesions and the rest 50 patients were diagnosed with benign nodules. Compared to CECT as a single imaging modality, the combined modalities showed a higher degree of sensitivity and accuracy, and the difference was statistically significant (sensitivity: $p=0.03$; accuracy: $p=0.02$); in the malignant cases, the magnitudes of contrast enhancement of CT and

ultrasound imaging decreased with an increase in the degree of differentiation, indicating a negative correlation between these factors.

Limitation of the study: This study only included a relatively modest number of cases; according to the pathological results, most of the malignant nodules were HCCs, and thus there was a very limited proportion of other pathological patterns. More cases should be included to expand the sample size, thereby further studying the clinical value of using CECT combined with CEUS for characterization and diagnosis of malignant nodules with different pathological patterns. Additionally, CEUS is still in the early stage of clinical application, and the performance of ultrasound imaging can be affected by many factors. To produce a highly objective and scientific research, further improvements will be made, such as expanding the sample size, and discussing different pathological patterns in this study.

CONCLUSION

The combined imaging modalities not only have a higher coincidence rate when being used for the characterization of small liver nodules, but also surpass the single imaging modality in screening sensitivity and diagnostic accuracy. CECT and CEUS are complementary to each other in determining the degree of differentiation of malignant liver nodules. The use of CECT combined with CEUS shows clinical value for characterizing small liver nodules and predicting the degree of malignancy.

Conflicts of interest: None.

Source of funding: None.

REFERENCES

1. Hafeez M, Nadeem M, Ahmed M, Faheem-Ur-Rehman. Hepatocellular Carcinoma (HCC), Where do we stand? Current situation. Pak J Med Sci. 2020;36(3):344-348. doi: 10.12669/pjms.36.3.1594
2. Hassan S, Zil-E-Rubab, Shah H, Shawana S. Dysregulated epidermal growth factor and tumor growth factor-beta receptor signaling through GFAP-ACTA2 protein interaction in liver fibrosis. Pak J Med Sci. 2020;36(4):782-787. doi:10.12669/pjms.36.4.1845
3. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology. 2018;67(1):401-421. doi:10.1002/hep.29487
4. Ko Y, Kim J, Park JK, Kim H, Cho JY, Kang SB, et al. Limited detection of small (≤ 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection. PLoS One. 2017;12(12):e0189797. doi: 10.1371/journal.pone.0189797

5. Anter AM, Hassenian AE. CT liver tumor segmentation hybrid approach using neutrosophic sets, fast fuzzy c-means and adaptive watershed algorithm. *Artif Intell Med*. 2019;97:105-117. doi:10.1016/j.artmed.2018.11.007
6. Durot I, Wilson SR, Willmann JK. Contrast-enhanced ultrasound of malignant liver lesions. *Abdom Radiol (NY)*. 2018;43(4):819-847. doi:10.1007/s00261-017-1360-8
7. Lo AA, Lo EC, Li H, Zhang W, Liao J, Rao MS, et al. Unique morphologic and clinical features of liver predominant/primary small cell carcinoma--autopsy and biopsy case series. *Ann Diagn Pathol*. 2014;18(3):151-156. doi: 10.1016/j.anndiagpath.2014.02.007
8. Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. *World J Gastroenterol*. 2016;22(42):9279-9287. doi: 10.3748/wjg.v22.i42.9279
9. Dietrich CF, Potthoff A, Helmlinger T, Ignee A, Willmann JK; CEUS LI-RADS Working Group. Standardisierte Befundung und Dokumentation der Kontrastmittelsonografie der Leber (CEUS LI-RADS) [Contrast-enhanced ultrasound: Liver Imaging Reporting and Data System (CEUS LI-RADS)]. *Z Gastroenterol*. 2018;56(5):499-506. doi:10.1055/s-0043-124874
10. Dubinsky TJ, Revels J, Wang S, Toia G, Sonneborn R, Hippe DS, et al. Comparison of Superb Microvascular Imaging with Color Flow and Power Doppler Imaging of Small Hepatocellular Carcinomas. *J Ultrasound Med*. 2018;37(12):2915-2924. doi: 10.1002/jum.14654
11. Wildner D, Schellhaas B, Strack D, Goertz RS, Pfeifer L, Fiessler C, et al. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS). *Clin Hemorheol Microcirc*. 2019;71(1):39-51. doi: 10.3233/CH-180378
12. Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, et al. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. *Eur Radiol*. 2020;30(1):558-570. doi:10.1007/s00330-019-06347-w
13. Montal R, Andreu-Oller C, Bassaganyas L, Esteban-Fabro R, Moran S, Montironi C, et al. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. *Br J Cancer*. 2019;121(4):340-343. doi:10.1038/s41416-019-0513-7
14. Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, Jang HJ, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. *Clin Mol Hepatol*. 2017;23(4):280-289. doi: 10.3350/cmh.2017.0037
15. Ayuso C, Rimola J, Vilana R, Burrell M, Darnell A, Garcia-Criado A, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines [published correction appears in *Eur J Radiol*. 2019;112:229]. *Eur J Radiol*. 2018;101:72-81. doi: 10.1016/j.ejrad.2018.01.025
16. Sweeney N, Marchant S, Martinez JD. Intraperitoneal injections as an alternative method for micro-CT contrast enhanced detection of murine liver tumors. *Biotechniques*. 2019;66(5):214-217. doi: 10.2144/btn-2018-0162
17. Chen X, Yang Z, Deng J. Use of 64-Slice Spiral CT Examinations for Hepatocellular Carcinoma (DR LU). *J BUON*. 2019;24(4):1435-1440.
18. Li L, Liu LZ, Xie ZM, Mo YX, Zheng L, Ruan CM, et al. Multi-phasic CT arterial portography and CT hepatic arteriography improving the accuracy of liver cancer detection. *World J Gastroenterol*. 2004;10(21):3118-3121. doi: 10.3748/wjg.v10.i21.3118
19. Wang DC, Jang HJ, Kim TK. Characterization of Indeterminate Liver Lesions on CT and MRI with Contrast-Enhanced Ultrasound: What Is the Evidence? *Am J Roentgenol*. 2020;214(6):1295-1304. doi: 10.2214/AJR.19.21498
20. Zarzour JG, Porter KK, Tchelepi H, Robbin ML. Contrast-enhanced ultrasound of benign liver lesions. *Abdom Radiol (NY)*. 2018;43(4):848-860. doi: 10.1007/s00261-017-1402-2
21. Jung EM, Clevert DA. Kontrastmittelsonographie (CEUS) und Bildfusion zur Durchführung von Leberinterventionen [Contrast-enhanced ultrasound (CEUS) and image fusion for procedures of liver interventions]. *Radiologe*. 2018;58(6):538-544. doi:10.1007/s00117-018-0411-7
22. Dietrich CF, Tana C, Caraianni C, Dong Y. Contrast enhanced ultrasound (CEUS) imaging of solid benign focal liver lesions. *Expert Rev Gastroenterol Hepatol*. 2018;12(5):479-489. doi: 10.1080/17474124.2018.1464389
23. Dietrich CF. Contrast-Enhanced Ultrasound of Benign Focal Liver Lesions. *Kontrastmittelsonografie benigner Lebertumoren*. *Ultraschall Med*. 2019;40(1):12-29. doi: 10.1055/a-0668-5746
24. Fröhlich E, Jenssen C, Schuler A, Dietrich CF. Kontrastmittelsonografie zur Charakterisierung von Lebertumoren: Praktische Aspekte [Contrast-enhanced ultrasound for characterisation of focal liver lesions, practical advice]. *Z Gastroenterol*. 2015;53(9):1099-1107. doi: 10.1055/s-0035-1553491
25. Westwood M, Joore M, Grutters J, Redekop K, Armstrong N, Lee K, et al. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: A systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2013;17(16):1-243. doi: 10.3310/hta17160

Authors' Contributions:

JLL & XJZ: Designed this study and prepared this manuscript, and are responsible and accountable for the accuracy or integrity of the work.
DB: Collected and analyzed clinical data.
ZLX: Significantly revised this manuscript.

-
1. Jia-lian Liu,
 2. Dong Bao,
 3. Zong-li Xu,
 4. Xiang-ju Zhuge
Department of Imaging,
Linyi Maternal and Child Health Hospital,
Linyi, Shandong, 276400,
P.R. China.
- 1-3: Department of Imaging, Linyi Central Hospital,
Linyi, Shandong, 276400,
P.R. China.

Correspondence:

Xiang-ju Zhuge,
Department of Imaging,
Linyi Maternal and Child Health Hospital,
Linyi, Shandong, 276400,
P.R. China.
E-mail: jifenwenfeibeng@163.com